Moderna (MRNA) announced “positive” preliminary immunogenicity data for the 2025-2026 formula of Spikevax, which targets the LP.8.1 variant of SARS-CoV-2 to help prevent COVID-19. “The data from an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback